San Francisco-area biotech gets new cash to launch clinical program for congenital sugar processing disease

A rare disease biotech from the suburbs of San Francisco has returned to the venture well for a Series B extension, aiming to get its lead program through its first clinical trials.

Glycomine pulled in a new $35 million haul for the studies, the biotech announced Wednesday morning, and plans...

Click to view original post